{"id":"https://openalex.org/A5115767587","orcid":"https://orcid.org/0009-0006-2688-3958","observed_orcids":["https://orcid.org/0009-0006-2688-3958"],"display_name":"Lotanna Ezeja","raw_author_names":["Ezeja, Lotanna","L. Ezeja","Lotanna Ezeja","Lotanna V. Ezeja"],"full_name":"Lotanna Ezeja","works_count":13,"cited_by_count":15,"summary_stats":{"2yr_mean_citedness":1.1538461538461537,"h_index":2,"i10_index":1},"ids":{"openalex":"https://openalex.org/A5115767587","orcid":"https://orcid.org/0009-0006-2688-3958","observed_orcids":["https://orcid.org/0009-0006-2688-3958"]},"affiliations":[{"institution":{"id":"https://openalex.org/I82497590","ror":"https://ror.org/02v80fc35","display_name":"Auburn University","country_code":"US","type":"education","lineage":["https://openalex.org/I82497590"]},"years":[2026,2025]}],"last_known_institutions":[{"id":"https://openalex.org/I82497590","ror":"https://ror.org/02v80fc35","display_name":"Auburn University","country_code":"US","type":"education","lineage":["https://openalex.org/I82497590"]}],"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","count":6,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10827","display_name":"Patient-Provider Communication in Healthcare","count":3,"subfield":{"id":"https://openalex.org/subfields/3600","display_name":"General Health Professions"},"field":{"id":"https://openalex.org/fields/36","display_name":"Health Professions"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","count":3,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","count":3,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10508","display_name":"Patient Safety and Medication Errors","count":2,"subfield":{"id":"https://openalex.org/subfields/3604","display_name":"Emergency Medical Services"},"field":{"id":"https://openalex.org/fields/36","display_name":"Health Professions"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"topic_share":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","value":3.4e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","value":2.27e-05,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","value":1.16e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11243","display_name":"Respiratory viral infections research","value":1.13e-05,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","value":9.3e-06,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"x_concepts":[{"id":"71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","score":0.95660001039505},{"id":"197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","score":0.8137000203132629},{"id":"177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","score":0.5220000147819519},{"id":"126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","score":0.5074999928474426},{"id":"2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","score":0.49000000953674316}],"counts_by_year":[{"year":2025,"works_count":6,"oa_works_count":3,"cited_by_count":4},{"year":2026,"works_count":7,"oa_works_count":4,"cited_by_count":11}],"display_name_alternatives":["Ezeja, Lotanna","L. Ezeja","Lotanna Ezeja","Lotanna V. Ezeja"],"block_key":"l ezeja","works_api_url":"https://api.openalex.org/works?filter=author.id:A5115767587","updated_date":"2026-11-01T11:00:13","created_date":"2025-01-05T00:00:00"}